CliffBio
small molecule

VIEKIRA XR

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

Loss of exclusivityJanuary 2035latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIEKIRA XR
Active ingredientDASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
StrengthEQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
9744170January 2035product
10105365January 2035product
9333204January 2035product
8466159September 2032use U-1637
8492386September 2032use U-1840
8685984September 2032use U-1840
8680106September 2032use U-1637
10201541May 2032product
10201584May 2032use U-1889
8691938April 2032substance, product
8686026June 2031product
8420596April 2031substance, product
9044480April 2031use U-1638
9006387June 2030use U-1687
8642538September 2029substance, product
8188104May 2029substance, product
9139536November 2028use U-1753
8501238September 2028substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIEKIRA XR patent cliff — loss of exclusivity January 2035 | CliffBio